Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for CinCor Pharma

    Client Virtual Booth

    CINCOR PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    CinCor Pharma
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    230 Third Avenue 6th Floor Waltham, MA 02451
    Telephone
    Telephone
    513-800-2585
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cincor.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cincor/
    Twitter
    Twitter
    https://twitter.com/cincorpharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Ex-CinCor CEO Marc de Garidel lands at Abivax after negotiating $1.8B cash sale
    Ex-CinCor CEO Marc de Garidel lands at Abivax after negotiating $1.8B cash sale

    https://endpts.com/after-negotiating-1-8b-cash-sale-ex-cincor-ceo-marc-de-garidel-lands-at-abivax/

    Amber Tong ENDPTS
    06 Apr 2023
    Share Share
    AstraZeneca Acquires CinCor for $1.3B Upfront
    AstraZeneca Acquires CinCor for $1.3B Upfront

    https://www.contractpharma.com/contents/view_breaking-news/2023-03-03/astrazeneca-acquires-cincor-for-13b-upfront/?widget=listSection

    CONTRACT PHARMA
    03 Mar 2023
    Share Share
    CinCor Announces Receipt of Minutes with FDA on Planned PIII of Baxdrostat
    CinCor Announces Receipt of Minutes with FDA on Planned PIII of Baxdrostat

    https://www.globenewswire.com/news-release/2023/02/21/2612072/0/en/CinCor-Pharma-Announces-Receipt-of-Minutes-from-End-of-Phase-2-Meeting-with-the-U-S-Food-and-Drug-Administration-on-Planned-Phase-3-Program-of-Baxdrostat.html

    GLOBENEWSWIRE
    21 Feb 2023
    Share Share
    AstraZeneca eagerness for CinCor revealed in larger first offer
    AstraZeneca eagerness for CinCor revealed in larger first offer

    https://www.fiercebiotech.com/biotech/behind-deal-astrazenecas-eagerness-cincor-acquisition-revealed-larger-initial-offer

    James Waldron FIERCE BIOTECH
    24 Jan 2023
    Share Share
    How the price of AstraZeneca's buyout of Cincor fell by $1.4B
    How the price of AstraZeneca's buyout of Cincor fell by $1.4B

    https://endpts.com/how-the-price-of-astrazenecas-buyout-of-cincor-fell-by-1-4b/

    Nicole DeFeudis ENDPTS
    23 Jan 2023
    Share Share
    AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
    AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.

    https://www.businesswire.com/news/home/20230122005024/en

    BUSINESSWIRE
    23 Jan 2023
    Share Share
    AstraZeneca to acquire CinCor Pharma in nearly $2 billion deal
    AstraZeneca to acquire CinCor Pharma in nearly $2 billion deal

    https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquire-cincor-for-cardiorenal-asset.html

    PRESS RELEASE
    10 Jan 2023
    Share Share
    CinCor Pharma to be Acquired by AstraZeneca
    CinCor Pharma to be Acquired by AstraZeneca

    https://www.globenewswire.com/news-release/2023/01/09/2584810/0/en/CinCor-Pharma-to-be-Acquired-by-AstraZeneca.html

    GLOBENEWSWIRE
    09 Jan 2023
    Share Share
    CinCor's hypertension drug loses halo after phase 2 fail
    CinCor's hypertension drug loses halo after phase 2 fail

    https://www.fiercebiotech.com/biotech/cincors-hypertension-drug-loses-its-halo-after-phase-2-fail-plunging-stock-44

    James Waldron FIERCEBIOTECH
    29 Nov 2022
    Share Share
    CinCor Announces Topline Data for Phase 2 HALO Trial Evaluating Baxdrostat
    CinCor Announces Topline Data for Phase 2 HALO Trial Evaluating Baxdrostat

    https://www.globenewswire.com//news-release/2022/11/28/2563048/0/en/CinCor-Pharma-Announces-Topline-Data-for-Phase-2-HALO-Trial-Evaluating-Selective-Aldosterone-Synthase-Inhibitor-Baxdrostat-in-Uncontrolled-Hypertension.html

    GLOBENEWSWIRE
    28 Nov 2022
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search